When to Order Imaging for Demyelinating Diseases: ACR Appropriateness Decoded
When to Order Imaging for Demyelinating Diseases: ACR Appropriateness Decoded
It’s late in a busy shift, and you’re evaluating a patient with new-onset, subacute neurologic symptoms—perhaps weakness, paresthesias, or visual changes. A demyelinating disease like multiple sclerosis (MS) is on the differential, but the next step is critical. Do you order an MRI of the brain, the spine, or both? With or without contrast? Choosing the most effective initial imaging study is key to a timely diagnosis and avoiding unnecessary radiation or delays in care. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria for demyelinating diseases to help you make the right call.
What Does ACR Demyelinating Diseases Cover?
The ACR Appropriateness Criteria for Demyelinating Diseases provide evidence-based guidelines for imaging patients with suspected or known disorders affecting the myelin of the central or peripheral nervous system. The scope of this topic is focused on common clinical presentations that prompt a workup for these conditions.
This document specifically addresses:
- Initial imaging for adults with symptoms suggesting a central nervous system (CNS) demyelinating event, such as a clinically isolated syndrome (CIS) or transverse myelitis.
- Surveillance imaging for adults with a known diagnosis of a demyelinating disease who are clinically stable.
- Imaging for patients with a known diagnosis who present with new or worsening neurologic deficits.
- Initial workup for adults with symptoms concerning for a peripheral nervous system (PNS) demyelinating disease, such as Guillain-Barré syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP).
These guidelines do not cover pediatric-specific demyelinating conditions or other neurologic presentations like stroke, tumor, or trauma, which are addressed in separate ACR documents.
What Imaging Should I Order for Demyelinating Diseases? Recommendations by Clinical Scenario
Choosing the correct imaging modality is crucial for diagnosing and managing demyelinating diseases. The ACR provides clear, scenario-based recommendations, with Magnetic Resonance Imaging (MRI) being the cornerstone of evaluation due to its superior soft-tissue contrast and ability to visualize demyelinating plaques. Computed Tomography (CT) is consistently rated as Usually not appropriate due to its low sensitivity for these lesions and its use of ionizing radiation.
For an adult with acute or subacute sensorimotor or brainstem symptoms and suspected CNS demyelinating disease, the ACR rates both MRI head without and with IV contrast and MRI cervical and thoracic spine without and with IV contrast as Usually appropriate. This comprehensive approach is vital for establishing dissemination in space—a key component of the McDonald criteria for diagnosing MS. The contrast helps identify active, gadolinium-enhancing lesions, indicating a breakdown of the blood-brain barrier and acute inflammation.
Similarly, for an adult with acute or subacute sensorimotor symptoms below a spinal cord level, suggesting transverse myelitis, both MRI head without and with IV contrast and MRI cervical and thoracic spine without and with IV contrast are Usually appropriate. Imaging the entire neuroaxis is critical because transverse myelitis can be the first presentation of MS or other conditions like neuromyelitis optica spectrum disorder (NMOSD).
In the context of surveillance, for an adult with a known demyelinating disease who has a stable neurologic examination, several options are considered Usually appropriate. These include MRI head without and with IV contrast, MRI head without IV contrast, MRI cervical and thoracic spine without and with IV contrast, and MRI cervical and thoracic spine without IV contrast. The choice often depends on clinical protocol and whether the goal is to monitor for silent disease progression, which may favor contrast administration. For more on spine imaging protocols, see our guide on MRI Cervical Spine Without Contrast.
When an adult with a known demyelinating disease presents with new or progressive neurologic deficits, imaging with contrast is paramount. The ACR rates MRI head without and with IV contrast and MRI cervical and thoracic spine without and with IV contrast as Usually appropriate to assess for new or enlarging lesions that correlate with the clinical relapse.
Finally, for an adult with acute or chronic symmetric weakness where a peripheral nervous system demyelinating disease is suspected, the focus shifts. MRI of the brachial plexus, lumbosacral plexus, cervical/thoracic spine, and lumbar spine, all without and with IV contrast, are rated as Usually appropriate. These studies can reveal nerve root thickening and enhancement characteristic of conditions like GBS or CIDP. While not the primary modality, a guide to cross-sectional brain imaging can be found here: CT Brain Without Contrast.
ACR Imaging Recommendations Table
| Clinical Scenario | Top Procedure | ACR Rating | Adult RRL | Pediatric RRL |
|---|---|---|---|---|
| Adult. Acute or subacute sensorimotor or brainstem symptoms. Suspect demyelinating disease of the central nervous system. Initial imaging. | MRI head without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Acute or subacute sensorimotor symptoms below a spinal cord level. Suspect transverse myelitis. Initial imaging. | MRI cervical and thoracic spine without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Known demyelinating disease. Stable neurologic examination. Surveillance imaging. | MRI head without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Known demyelinating disease. New or progressive neurologic deficits. Initial imaging. | MRI head without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Acute or chronic symmetric weakness. Suspect demyelinating disease of the peripheral nervous system. Initial imaging. | MRI lumbosacral plexus without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
Adult vs. Pediatric Demyelinating Diseases Imaging: Radiation Dose Tradeoffs
The ACR guidelines for demyelinating diseases are primarily focused on adult presentations, but pediatric considerations are crucial, especially regarding radiation safety. Fortunately, the mainstay of diagnosis and monitoring—MRI—does not use ionizing radiation (0 mSv). This makes it the ideal modality for all age groups and for patients requiring serial imaging over their lifetime, aligning perfectly with the As Low As Reasonably Achievable (ALARA) principle.
In the rare instances where CT might be considered (e.g., to rule out acute hemorrhage in a patient with contraindications to MRI), the radiation dose becomes a significant factor. The ACR provides distinct pediatric relative radiation level (RRL) estimates, which are typically lower than adult levels due to size-adjusted protocols. For example, a CT head delivers an estimated 1-10 mSv in adults but a lower 0.3-3 mSv in children. While CT is rated Usually not appropriate for diagnosing demyelinating disease, understanding these dose differences is essential for any clinician ordering imaging for younger patients. Minimizing cumulative radiation exposure is a primary goal in pediatric medicine to reduce the potential long-term risk of malignancy.
Imaging Protocol Details for Demyelinating Diseases
Once you’ve decided on the right study based on the clinical scenario, ensuring it is performed with the correct protocol is the next critical step. A dedicated MS protocol, for instance, includes specific sequences like FLAIR (Fluid-Attenuated Inversion Recovery) and post-contrast T1-weighted images optimized to detect demyelinating plaques. Our protocol guides provide detailed information on technique, contrast administration, and interpretation principles for the studies recommended in this document.
Tools to Help You Order the Right Study
Navigating imaging guidelines at the point of care can be challenging. GigHz offers several resources designed to support clinical decision-making and streamline the ordering process.
The ACR Appropriateness Criteria Lookup tool provides a searchable interface for the full library of ACR guidelines, extending far beyond demyelinating diseases. It helps you quickly find evidence-based recommendations for hundreds of clinical scenarios you encounter daily.
For detailed procedural information, the Imaging Protocol Library offers in-depth guides on how specific studies are performed. This resource is invaluable for understanding the technical aspects of an order and for communicating effectively with radiology technologists and radiologists.
To help with patient communication about radiation exposure, especially when CT is considered, the Radiation Dose Calculator allows you to estimate and track cumulative radiation dose from various imaging studies. This supports informed consent discussions and adherence to the ALARA principle.
Why is CT rated ‘Usually not appropriate’ for suspected demyelinating disease?
CT is rated as ‘Usually not appropriate’ for two main reasons. First, it has very low sensitivity for detecting demyelinating plaques, especially in the posterior fossa and spinal cord. MRI, particularly with FLAIR sequences, is far superior. Second, CT uses ionizing radiation, which should be avoided when a non-radiation alternative like MRI provides better diagnostic information. CT’s primary role in this context is limited to emergent situations to rule out other pathologies like hemorrhage if MRI is unavailable or contraindicated.
Is intravenous contrast always necessary for an initial MS workup?
Yes, for an initial diagnostic workup, intravenous gadolinium-based contrast is essential. The ACR rates MRI of the brain and spine ‘without and with IV contrast’ as ‘Usually appropriate.’ Contrast helps identify actively inflamed lesions, which appear as enhancing plaques. This is crucial for determining disease activity and satisfying the ‘dissemination in time’ component of the McDonald diagnostic criteria, as the presence of both enhancing and non-enhancing lesions implies multiple attacks over time.
If a patient’s symptoms are limited to their legs, do I still need to image the brain?
Yes. Even if the clinical presentation suggests a spinal cord lesion (e.g., transverse myelitis), imaging the brain is ‘Usually appropriate.’ Demyelinating diseases like MS are defined by the dissemination of lesions in both space (different parts of the CNS) and time. A brain MRI is necessary to look for clinically silent lesions that would support a diagnosis of MS and to rule out other mimics. The presence of periventricular, juxtacortical, or infratentorial lesions is a key diagnostic criterion.
How often should a stable patient with known MS get surveillance imaging?
The optimal frequency is not definitively established and often depends on the patient’s specific clinical course, disease-modifying therapy, and institutional protocols. The ACR lists surveillance imaging for stable patients as ‘Usually appropriate.’ Many neurologists perform routine surveillance MRI of the brain (and sometimes spine) annually or every two years to monitor for subclinical disease activity (new T2 lesions), which may prompt a change in treatment even in the absence of a clinical relapse.
What is the role of MRI in suspected peripheral nervous system (PNS) demyelination like GBS?
While the diagnosis of Guillain-Barré syndrome (GBS) and CIDP is primarily clinical, supported by electrodiagnostic studies and CSF analysis, MRI plays an important supportive role. For suspected PNS demyelination, the ACR finds MRI of the relevant plexus (brachial or lumbosacral) and spine ‘without and with IV contrast’ to be ‘Usually appropriate.’ The characteristic finding is thickening and enhancement of the nerve roots of the cauda equina and cranial nerves, which can help confirm the diagnosis and exclude mimics like spinal cord compression.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026
